P1023: AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM): EFFICACY AND SAFETY ANALYSES FROM THE PHASE 2 PATHFINDER STUDY WITH 2-YEAR FOLLOW-UP

• Jason Gotlib,
• Andreas Reiter,
• Deepti Radia,
• Michael Deininger,
• Tracy George,
• Jens Panse,
• Alessandro Vannucchi,
• Uwe Platzbecker,
• Ivan Alvarez-Twose,
• Andrzej Mital,
• Olivier Hermine,
• Ingunn Dybedal,
• Elizabeth O. Hexner,
• Lambert Span,
• Ruben Mesa,
• Prithviraj Bose,
• Kirsten Pettit,
• Stephen Oh,
• Hui-Min Lin,
• Sasa Dimitrijevic,
• Javier Muñoz-González,
• Daniel J. Deangelo

Affiliations

Jason Gotlib

1 Stanford Cancer Institute/Stanford University School of Medicine, Division of Hematology, Stanford, United States

Andreas Reiter

2 University Hospital Mannheim, Heidelberg University, Department of Hematology and Oncology, Heidelberg, Germany

Deepti Radia

3 Guy’s & St Thomas’s NHS Foundation Trust, London, United Kingdom

Michael Deininger

4 Versiti Blood Research Institute, Milwaukee, United States

Tracy George

5 ARUP Laboratories, University of Utah, Salt Lake City, United States

Jens Panse

6 University Hospital Aachen, Medical Faculty, RWTH Aachen University, Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, Aachen, Germany

Alessandro Vannucchi

7 Azienda Ospedaliera Universitaria Careggi, University of Florence, Center for Research and Innovation of Myeloproliferative Neoplasms – CRIMM, Florence, Italy

Uwe Platzbecker

8 Leipzig University, Leipzig, Germany

Ivan Alvarez-Twose

9 Institute of Mastocytosis Studies of Castilla-La Mancha, Spanish Reference Center of Mastocytosis, Toledo, Spain

Andrzej Mital

10 Medical University of Gdansk, Department of Hematology and Transplantology, Gdansk, Poland

Olivier Hermine

11 Necker–Enfants Malades Hospital, APHP, and Imagine Institute, Department of Hematology, CEREMAST, Paris, France

Ingunn Dybedal

12 Oslo University Hospital, Department of Hematology, Oslo, Norway

Elizabeth O. Hexner

13 Abramson Cancer Center, University of Pennsylvania, Philadelphia, United States

Lambert Span

14 University Medical Center Groningen, Department of Hematology, Groningen, The Netherlands

Ruben Mesa

15 Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, United States

Prithviraj Bose

16 The University of Texas MD Anderson Cancer Center, Houston, United States

Kirsten Pettit

17 University of Michigan, Division of Hematology/Oncology, Ann Arbor, United States

Stephen Oh

18 Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, United States

Hui-Min Lin

19 Blueprint Medicines Corporation, Cambridge, United States

Sasa Dimitrijevic

20 Blueprint Medicines (Switzerland) GmbH, Zug, Switzerland

Javier Muñoz-González

20 Blueprint Medicines (Switzerland) GmbH, Zug, Switzerland

Daniel J. Deangelo

21 Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, United States